Olympus Corporation (TYO:7733)
Japan
· Delayed Price · Currency is JPY 1,978.00
+36.00 (1.85%)
May 9, 2025, 3:30 PM JST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Total Medical Solutions Division | 982.28B |
Log In |
Log In |
Log In |
Log In |
| Total Medical Solutions Division Growth | 8.70% |
Log In |
Log In |
Log In |
Log In |
| Scientific Solutions Division | - |
Log In |
Log In |
Log In |
Log In |
| Scientific Solutions Division Growth | - |
Log In |
Log In |
Log In |
Log In |
| Other Division Revenue (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| Other Division Revenue (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Endoscopic Solutions Division | 626.83B |
Log In |
Log In |
Log In |
Log In |
| Endoscopic Solutions Division Growth | 9.56% |
Log In |
Log In |
Log In |
Log In |
| Therapeutic Solutions Division | 355.45B |
Log In |
Log In |
Log In |
Log In |
| Therapeutic Solutions Division Growth | 7.23% |
Log In |
Log In |
Log In |
Log In |
| Other Division Revenue (Post-FY2024 Reporting) | 601.00M |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Total Medical Solutions Division Operating Profit | 165.05B |
Log In |
Log In |
Log In |
Log In |
| Total Medical Solutions Division Operating Profit Growth | 31.99% |
Log In |
Log In |
Log In |
Log In |
| Scientific Solutions Division Operating Profit | - |
Log In |
Log In |
Log In |
Log In |
| Scientific Solutions Division Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In |
| Other Division Operating Profit (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| Other Division Operating Profit (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Eliminations from Division Operating Profit | -41.98B |
Log In |
Log In |
Log In |
Log In |
| Eliminations from Division Operating Profit Growth | -2.54% |
Log In |
Log In |
Log In |
Log In |
| Endoscopic Solutions Division Operating Profit | 115.00B |
Log In |
Log In |
Log In |
Log In |
| Endoscopic Solutions Division Operating Profit Growth | -8.48% |
Log In |
Log In |
Log In |
Log In |
| Therapeutic Solutions Division Operating Profit | 50.06B |
Log In |
Log In |
Log In |
Log In |
| Therapeutic Solutions Division Operating Profit Growth | -8442.83% |
Log In |
Log In |
Log In |
Log In |
| Other Division Operating Profit (Post-FY2024 Reporting) | -877.00M |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Japan | 112.05B |
Log In |
Log In |
Log In |
Log In |
| Japan Growth | -7.88% |
Log In |
Log In |
Log In |
Log In |
| North America | 405.27B |
Log In |
Log In |
Log In |
Log In |
| North America Growth | 21.88% |
Log In |
Log In |
Log In |
Log In |
| Europe | 252.51B |
Log In |
Log In |
Log In |
Log In |
| Europe Growth | 10.68% |
Log In |
Log In |
Log In |
Log In |
| Asia and Oceania Revenue (Pre-FY2020 Reporting) | 186.84B |
Log In |
Log In |
Log In |
Log In |
| Asia and Oceania Revenue (Pre-FY2020 Reporting) Growth | -7.40% |
Log In |
Log In |
Log In |
Log In |
| Other Countries | 29.05B |
Log In |
Log In |
Log In |
Log In |
| Other Countries Growth | 18.97% |
Log In |
Log In |
Log In |
Log In |
| China | 93.09B |
Log In |
Log In |
Log In |
Log In |
| China Growth | -20.25% |
Log In |
Log In |
Log In |
Log In |
| Asia and Oceania Revenue (Post-FY2019 Reporting) | 93.75B |
Log In |
Log In |
Log In |
Log In |
| Asia and Oceania Revenue (Post-FY2019 Reporting) Growth | 10.25% |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Company's Total Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| ESD - Medical Service Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| TSD - Urology Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| TSD - Respiratory Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |
| TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment |
Log In |
Log In |
Log In |
Log In |